Alzheimer's drug Leqembi

Recent studies presented by Eisai and Biogen at the Alzheimer's Association International Conference reveal that the Alzheimer's medication Leqembi significantly slows cognitive decline in early-stage patients, demonstrating a 31% reduction over three years compared to untreated individuals. This builds on earlier findings showing a 27% decline reduction after 18 months, emphasizing the necessity for long-term treatment to maintain benefits. The data also indicate that discontinuing Leqembi leads to worsening health and cognitive decline, while side effects like brain swelling diminish after six months. This contrasts with Eli Lilly's Kisunla, which allows for discontinuation after amyloid levels decrease. Despite the promising results, experts remain cautious about whether the benefits will persuade doctors to adopt continuous treatment. The study underscores the ongoing debate in the field regarding long-term medication strategies for Alzheimer's care.